Inclusion Criteria:

- Disease Status: NHL, HD, MM that are chemorefractory or relapsed; CLL that is Rai
stage III or IV, or lymphocyte doubling time of 6 months, or stage I/II resistant to
> 2 cycles of chemotherapy regimens; CML in accelerated or blast phase; MDS with
life-threatening cytopenias; patients who have had a previous autologous or
allogeneic bone marrow or stem cell transplant; other hematological disorders where
allogeneic transplant is appropriate and the risk of conventional transplantation is
considered to be unacceptably high.

- estimated disease free survival of less than one year

- ECOG performance status of 0, 1, or 2

- HLA 1 to 3 mismatched (at A, B, DR loci) related donor

Exclusion Criteria:

- Cardiac disease: symptomatic congestive heart failure, ejection fraction of < 45%,
active angina pectoris or uncontrolled hypertension.

- Pulmonary disease: severe chronic obstructive lung disease, or symptomatic
restrictive lung disease, or corrected DLCO of < 50%

- Renal disease: serum creatinine > 2.0 mg/dl or creatinine clearance < 50 ml/min

- Hepatic disease: serum bilirubin > 2.0 mg/dl or alkaline phosphate, SGPT or SGOT > 3
x normal

- Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other
neuropsychiatric abnormalities believed to preclude transplantation

- HIV antibody or Hepatitis B surface antigen positivity

- Uncontrolled infection

- Presence of HAMA or HAHA in patient previously treated with monoclonal antibody
therapy or who have received a product in which the preparation involved a monoclonal
antibody affinity step